Allkindza/E+ via Getty Images Constellation Energy ( CEG ) down 2.2% pre-market Tuesday after issuing guidance for FY 2026 adjusted earnings of $11-$12/share, the midpoint of which is below the $11.73 FactSet analyst consensus estimate. In presentation slides , Constellation ( CEG ) also said it forecasts a base earnings compound annual growth rate of 20% during 2026-29 and sees $3.9B of growth c...
Allkindza/E+ via Getty Images Constellation Energy ( CEG ) down 2.2% pre-market Tuesday after issuing guidance for FY 2026 adjusted earnings of $11-$12/share, the midpoint of which is below the $11.73 FactSet analyst consensus estimate. In presentation slides , Constellation ( CEG ) also said it forecasts a base earnings compound annual growth rate of 20% during 2026-29 and sees $3.9B of growth capital expenditures to be invested. The company also increased its stock repurchase plan authorization to $5B. Constellation ( CEG ), which operates the largest U.S. nuclear fleet, also said it has secured more than 5,650 MW of long-term clean energy agreements, including nuclear, geothermal and battery storage. More on Constellation Energy Constellation Energy: Nuclear And Electric Demand Strength Is Going Nowhere Constellation Energy: Risk Of Disappointment On March 31, Retain Sell Constellation Energy: Skip This Stock If You Want Returns
(RTTNews) - While reporting unaudited financial results for the fourth quarter on Tuesday, branded therapeutics company Keenova Therapeutics plc (MNK) said it expects net sales for the full-year 2026 between $1.94 billion and $2.00 billion, and adjusted EBITDA between $730 millio
(RTTNews) - While reporting unaudited financial results for the fourth quarter on Tuesday, branded therapeutics company Keenova Therapeutics plc (MNK) said it expects net sales for the full-year 2026 between $1.94 billion and $2.00 billion, and adjusted EBITDA between $730 millio
AlTi Global press release ( ALTI ): Q4 GAAP EPS of -$0.20. Revenue of $88.26M (+71.5% Y/Y) beats by $1.66M . Q4 Adjusted EBITDA nearly doubled sequentially to $11 million. AUM of $50B increased 10% YoY primarily associated with strong market performance and the acquisition of Kontora. More on AlTi Global Seeking Alpha’s Quant Rating on AlTi Global Historical earnings data for AlTi Global Financial...
AlTi Global press release ( ALTI ): Q4 GAAP EPS of -$0.20. Revenue of $88.26M (+71.5% Y/Y) beats by $1.66M . Q4 Adjusted EBITDA nearly doubled sequentially to $11 million. AUM of $50B increased 10% YoY primarily associated with strong market performance and the acquisition of Kontora. More on AlTi Global Seeking Alpha’s Quant Rating on AlTi Global Historical earnings data for AlTi Global Financial information for AlTi Global
The outbreak of the Iran war sparked heavy selling pressure across every European equity market through March, as investors gauge the potential impact of the continent's second energy price shock in four years. There has been little room to hide for European equity investors. Britain's FTSE 100 , which is more heavily tilted to oil and gas stocks, has held up slightly better than its peers on the ...
The outbreak of the Iran war sparked heavy selling pressure across every European equity market through March, as investors gauge the potential impact of the continent's second energy price shock in four years. There has been little room to hide for European equity investors. Britain's FTSE 100 , which is more heavily tilted to oil and gas stocks, has held up slightly better than its peers on the continent, falling 5% over the month compared to a 7% drop for both Germany's DAX and France's Cac 40 . Another equity market that has taken a significant bruising is the Swiss Market Index , which comprises the country's 20 largest listed companies. The SMI fell 7.5% in March, bottoming out around 13% lower on March 20 before paring some losses as the conflict continued to develop. And analysts at UBS believe the Swiss equity market is best-placed to benefit from a potential rebound in sentiment, they wrote in a note on Tuesday. UBS is the largest bank in Switzerland and is listed on the Swiss exchange. Its analysts see the recent correction as offering a good opportunity to enter Swiss equities, due to their more defensive sectoral exposure, which includes a mix of healthcare stocks and consumer staples. "Swiss equities are heavily weighted toward high-quality companies with strong balance sheets, resilient cash flows, and defensive sector exposure, characteristics that have historically helped the market navigate periods of geopolitical uncertainty and weaker economic growth," the analysts wrote. UBS said Swiss equity valuations, which now trade on around 16x forward earnings with dividend yields of around 3.2%, now look more appealing. Swiss stocks compare favorably with Swiss franc bond yields, which offer zero interest at present. For these reasons, UBS has upgraded Swiss equities to "attractive." The buy rating expands on an earlier note published March 24, which advocated for a move away from European equity markets. The analysts view the main European bourses as pr...
Trinity Capital Inc (Symbol: TRIN) has been named as a Top 10 dividend-paying financial stock, according to Dividend Channel, which published its most recent ''DividendRank'' report. The report noted that among shares of financial companies, TRIN displayed both attractive valu
Trinity Capital Inc (Symbol: TRIN) has been named as a Top 10 dividend-paying financial stock, according to Dividend Channel, which published its most recent ''DividendRank'' report. The report noted that among shares of financial companies, TRIN displayed both attractive valu
In this article BIIB APLS Follow your favorite stocks CREATE FREE ACCOUNT Signage outside the Biogen Inc. office in the Kendall Square neighborhood of Cambridge, Massachusetts, US, on Tuesday, Sept. 6, 2022. Adam Glanzman | Bloomberg | Getty Images Biogen has agreed to acquire Apellis Pharmaceuticals for about $5.6 billion in cash, expanding its portfolio of rare-disease medicines, the companie...
In this article BIIB APLS Follow your favorite stocks CREATE FREE ACCOUNT Signage outside the Biogen Inc. office in the Kendall Square neighborhood of Cambridge, Massachusetts, US, on Tuesday, Sept. 6, 2022. Adam Glanzman | Bloomberg | Getty Images Biogen has agreed to acquire Apellis Pharmaceuticals for about $5.6 billion in cash, expanding its portfolio of rare-disease medicines, the companies said on Tuesday. Under the terms of the deal, Apellis shareholders will receive $41 per share in cash, representing a premium of about 140% to the stock's last close. They are also eligible to receive two payments of $2 per share each, contingent on certain global sales milestones for Apellis' eye disorder drug Syfovre, the companies said. Shares of Apellis rose more than twofold in premarket trading. Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
In this article MSFT Follow your favorite stocks CREATE FREE ACCOUNT Microsoft has been hit with a fresh probe into its business software ecosystem by the British competition regulator. The U.K.'s Competition and Markets Authority announced on Tuesday it is launching a "strategic market status (SMS) investigation" into the tech giant's suite of enterprise software, starting in May. Hundreds of tho...
In this article MSFT Follow your favorite stocks CREATE FREE ACCOUNT Microsoft has been hit with a fresh probe into its business software ecosystem by the British competition regulator. The U.K.'s Competition and Markets Authority announced on Tuesday it is launching a "strategic market status (SMS) investigation" into the tech giant's suite of enterprise software, starting in May. Hundreds of thousands of U.K. businesses and public sector organisations use Microsoft's business software, which includes Windows, Word, Excel, Teams and AI platform Copilot, every day, the regulator said in a statement. "An SMS designation would enable us to tackle remaining concerns around Microsoft's licensing practices in cloud and would also enable us to ensure a level playing field as AI is rapidly embedded into everyday business software tools," CMA CEO Sarah Cardell said in a statement. Microsoft is committed to working "quickly and constructively" to address the issues identified by the CMA, said the company's president, Brad Smith. "We recognize that the CMA will continue to review and assess additional issues relating to our products and services, including in the business software market," Smith added in a statement. This is a breaking story. Refresh for updates. Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.